Lv22
200 积分 2026-03-10 加入
Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial
9天前
已完结
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
13天前
已完结
Asundexian versus Apixaban in Patients with Atrial Fibrillation
26天前
已完结
Global burden of metabolic diseases, 1990–2021
29天前
已完结
A novel polypeptide from stony coral Goniopora columna inhibits thrombosis by interfering with the contact-kinin pathway
1个月前
已完结
The therapeutic dilemma of basal cell carcinoma in older adults: A review of the current literature
1个月前
已完结
Bempedoic acid: new evidence and recommendations on use
1个月前
已完结
Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis
1个月前
已完结
FGF21 Analogues and MASLD: A Summary of Preclinical and Clinical Data
1个月前
已完结
FGF21 Analogues and MASLD: A Summary of Preclinical and Clinical Data
1个月前
已关闭
皖公网安备34019202002308
